The invention relates to novel crystalline HCl salts of Asenapine and to methods of their preparation. Furthermore the invention relates to the use of the novel salts in pharmaceutical compositions and the use of the novel salts in the treatment of psychotic diseases or disorders such as schizophrenia and acute mania associated with bipolar disorder.